导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 13.40% | 689/4751 |
| 近一周 | -1.75% | 2711/5440 |
| 近一月 | -6.96% | 4366/5397 |
| 近一季 | -19.68% | 4879/5207 |
| 近半年 | 1.54% | 1145/4896 |
| 近一年 | 25.64% | 310/4379 |
| 近两年 | 148.82% | 254/2947 |
| 近三年 | 92.05% | 197/2246 |
| 成立以来 | 62.65% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
6.14% 282/4961 |
47.91% 641/5312 |
- - |
- - |
| 2025 | 62.48% 181/4813 |
2.33% 1403/3635 |
5.56% 568/4076 |
42.18% 706/4524 |
5.78% 400/4813 |
| 2024 | 6.70% 1730/3463 |
-10.44% 2340/2808 |
-7.19% 2062/3014 |
30.34% 135/3129 |
-1.51% 1736/3463 |
| 2023 | -21.22% 1896/2656 |
1.50% 1563/2280 |
-10.22% 2095/2385 |
-11.79% 2090/2515 |
-1.98% 398/2655 |
| 2022 | -29.70% 1609/2207 |
-21.03% 1595/1919 |
8.15% 382/2016 |
-18.77% 1734/2113 |
1.33% 1303/2208 |
| 2021 | -2.93% 881/1822 |
-6.06% 973/1255 |
15.34% 227/1330 |
-15.36% 1385/1466 |
5.84% 262/1822 |
| 2020 | 59.03% 129/1250 |
7.71% 34/1028 |
33.90% 25/1067 |
4.64% 947/1164 |
5.38% 788/1184 |
| 2019 | 61.37% 47/1092 |
44.52% 28/754 |
-11.66% 771/804 |
11.92% 35/850 |
12.94% 33/918 |
| 2018 | -41.31% 615/834 |
- - |
- - |
- - |
-19.07% 662/691 |
| 2017 | 13.52% 262/714 |
- - |
- - |
- - |
- - |
| 2016 | -18.99% 429/605 |
- - |
- - |
- - |
- - |
| 2015 | 47.78% 23/575 |
- - |
- - |
- - |
- - |
| 2014 | 1.86% 229/237 |
- - |
- - |
- - |
- - |
| 2013 | 3.01% 62/186 |
- - |
- - |
- - |
- - |
| 2012 | 0.83% 108/140 |
- - |
- - |
- - |
- - |
| 2011 | -27.96% 84/102 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 大成深证成长40ETF VS. 长安沪深300非周期A(740101) |